ClinicalTrials.gg
RecruitingNCT07402265Updated Aug 21, 2026

Piloting a Brief, Online Intervention for Suicidality in Sexual and Gender Minority Youth

An interventional study of KindMind in Suicidal Thoughts, Sexual and Gender Minorities and Youth, sponsored by Western University. Recruiting at 1 site in Canada. Open to participants aged 13 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Western University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
13 Years to 25 Years
Sex
All
01

Study summary

Sexual and gender minority youth (i.e., LGBTQ+ individuals) are at elevated risk for suicidal thoughts compared to cisgender/heterosexual youth and there is increased demand for programs and treatments tailored to this population. The current study seeks to pilot a brief, online, self-guided intervention for suicidal thoughts designed for sexual and gender minority youth to test if this intervention is acceptable to this population and if completing this intervention significantly decreases suicidal thoughts.

Read the detailed description

The current study will pilot an intervention for suicidal thoughts in sexual and gender minority youth. We will recruit of a sample of sexual and gender minority youth who report experiencing recent thoughts of suicide. Participants will be asked to complete a battery of questionnaires including demographic questions and mental health symptom assessments, then complete the intervention, and finally complete additional questionnaires. One month after completing the intervention, participants will be asked to complete a series of questionnaires. This study is designed to evaluate the acceptability and initial effectiveness of this intervention and will not include a control group.

02

Conditions studied

  • Suicidal Thoughts
  • Sexual and Gender Minorities
  • Youth

Browse trials for

Keywords

  • Suicidal thoughts
  • Sexual and Gender Minorities
  • Youth
  • Brief
  • Online
  • Self-Guided
  • Self-Compassion
  • Self-Neutrality
03

In context

Suicidal Ideation

569 studies on the registry are indexed under Suicidal Ideation; 203 are open to participants now.

This study's planned enrollment of 250 is above the median of 80 across 469 interventional studies indexed under Suicidal Ideation.

Browse Suicidal Ideation studies →

Lead sponsor

Western University is the lead sponsor of 14 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident of Canada
  • Fluent in English
  • Youth (i.e., 13-25 years)
  • Identifies as a sexual and/or gender minority (i.e., any sexual identity excluding heterosexual and/or any gender identity excluding cisgender)
  • Endorses experiencing any suicidal ideation within the past 6 months
  • Access to a computer and able to participate virtually

Exclusion criteria

Exclusion Criteria:

  • Does not meet the inclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants will complete the online, self-guided program, which will take approximately 30 minutes and involve participants completing modules describing how to use self-compassion/self-neutrality techniques to reduce suicidal thoughts.

    Behavioral: KindMind

Interventions

  • BehavioralKindMind

    This intervention is hosted on Wix-com and involves multiple self-guided modules in which participants are taught how to use self-compassion and/or self-neutrality to reduce suicidal thoughts. This intervention is tailored to sexual and gender minority youth.

06

What researchers measure

Primary outcomes

  1. Suicidal Ideation Questionnaire - Junior

    Suicidal Ideation Questionnaire - Junior (SIQ-Jr; Reynolds, 1987). The SIQ-Jr was used to assess suicidal ideation in the current study. This self-report measure include 15 items of suicidal thoughts that are rated on a 7-item scale (i.e., Almost every day, couple of times a week, about once a week, couple of times a month, About once a month, I had this thought before but not in the past month, I never had this thought) of how frequency the respondent had each thought in their mind over the past month. Sample items include I thought about dying, I wished I were dead, and I thought about killing myself. The SIQ-Jr is scored by summing the responses to create a total score from 0-90, with higher scores indicating a higher severity of suicidal ideation.

    Time frame: From Baseline (i.e., before intervention administration) to four weeks after intervention administration.

Secondary outcomes

  1. Suicidal Ideation Thoughts and Behaviours Interview - Revised

    Suicidal Ideation Thoughts and Behaviours Interview - Revised (SITBI -R; Gratch et al., 2022). Select items from the SITBI-R will be administered to capture suicidal behaviour, including frequency and severity of suicide attempts.

    Time frame: From Baseline (i.e., before intervention administration) to four weeks after intervention administration.

  2. Self-Compassion Scale - Short Form

    Self-Compassion Scale - Short Form (SCS-SF; Raes et al., 2011). The SCS-SF is a 12-item measure that assesses trait self-compassion. Each item is rated on a 5-point scale of how the participant typically reacts to themselves during difficult times, ranging from Almost never to Almost Always. Six subscales are computed corresponding to the six components of self-compassion based on Neff's (2003) conceptualization: Self-Kindness, Self-Judgement, Common Humanity, Isolation, Mindfulness, and Overidentification. A total score is computed by averaging the six subscale total scores. Higher scores indicated higher self-compassion. Sample items include I try to see my failing as part of the human condition and I'm disapproving and judgmental about my own flaws and inadequacies.

    Time frame: From Baseline (i.e., before intervention administration) to four weeks after intervention administration.

  3. Patient Health Questionnaire - 9

    Patient Health Questionnaire - 9 (PHQ-9; Kroenke et al., 2001). The PHQ-9 a self-report assessment of depressive symptoms. The PHQ-9 includes nine items that ask participants to rate how frequently they experienced each problem (i.e., Little interest or pleasure in doing things, Feeling tired or having low energy) over the past two weeks, with a 4-point scale of frequency (i.e., Not at all, Several days, More than half the days, Nearly every day). A total score is summed and can range from 0-27. Higher total scores indicate greater severity of depressive symptoms. An additional item not included in the total score asks participants to rate how difficult the problems they indicated make it for them to do work, take care of things at home, and get along with other people.

    Time frame: From Baseline (i.e., before intervention administration) to four weeks after intervention administration.

  4. Hopelessness Scale for Children

    Hopelessness Scale for Children (HSC; Kazdin et al., 1983). The HSC includes 17 true/false items assessing hopelessness in children as young as 5 years old. Total scores are summed and the higher the total score, the greater the hopelessness for the future. Sample items include I will have more good times than bad times and I don't think I will get what I really want.

    Time frame: From Baseline (i.e., before intervention administration) to four weeks after intervention administration.

  5. Generalized Anxiety Disorder - 7

    Generalized Anxiety Disorder - 7 (GAD-7; Spitzer et al., 2006) . The GAD-7 is a self-report assessment of anxiety. The respondent indicates how often they have experienced each of seven listed symptoms over the past two weeks, including items such as Not being able to stop or control worrying and Becoming easily annoyed or irritable. Items are rated on a 4-point scale of frequency (i.e., Not at all, Several days, More than half the days, Nearly every day). Total scores range from 0-21, with higher scores indicating higher severity of anxiety. An additional item not included in the total score asks participants to rate how difficult the problems they indicated make it for them to do work, take care of things at home, and get along with other people.

    Time frame: From Baseline (i.e., before intervention administration) to four weeks after intervention administration.

  6. Difficulties in Emotion Regulation Scale - Short Form

    Difficulties in Emotion Regulation Scale - Short Form (DERS-SF; Kaufman et al., 2016). The DERS-SF is a self-report measure of difficulties regulating emotion. This measure has 18 items that are rated on a 5-point scale assessing how often each item applies to the participant, including the following options: Almost never (0-10%), Sometimes (11-35%), About half of the time (36-65%, Most of the time (66-90%), and Almost always (91-100%). The DERS-SF includes items such as When I'm upset, I have difficulty concentrating and I pay attention to how I feel. A total score and six subscale scores (Strategies, Nonacceptance, Impulse, Goals, Awareness, Clarity) are created by adding item scores and higher scores reflect greater difficulties with emotion regulation. Total scores range from 18-90.

    Time frame: From Baseline (i.e., before intervention administration) to four weeks after intervention administration.

Other outcomes

  1. Intervention Feedback Questions.

    After the intervention, participants will be asked several unstandardized feedback questions rated on a 5-point Likert Scale (i.e., Strongly Disagree, Disagree, Neither Agree or Disagree, Agree, Strongly Agree) about how acceptable, helpful, and engaging the intervention is. Participants will also be asked how likely to use the intervention they would be and how likely they are to recommend it to a friend.

    Time frame: Immediately following intervention administration

  2. Visual Analogue Scales

    Visual Analogue Scales (VAS). VAS are a measurement method that involves participants marking a point on a continuous line between two extreme points to indicate the intensity of a feeling or mood. For this study, all VAS involved a slider scale in which the participant could indicate a value between 0 and 100, with lower scores indicating lower intensity and higher scores indicating higher intensity. For example, to measure state sadness, participants were given the following instructions: Using the slider below, please indicate how sad you feel in this moment. Scores can range from 0-100. Lower scores indicate less sadness and higher scores indicate more sadness. VAS will be used to assess state self-compassion, self-neutrality, hopelessness, distress, anger, anxiety, sadness, tiredness, and desire to self-harm immediately before and after completing the intervention

    Time frame: From immediately before intervention administration to immediately after intervention administration.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Only de-identified IPD that is included in the published results of the study will be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2026, 7 months after the start.

Of 281 non-industry interventional studies with no phase under Suicidal Ideation, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 7 months is below that.

Counting every sponsor, half of 290 studies reached it within 29 months; a quarter within 13 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 11, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07402265
Lead sponsor
Western University
Collaborators
Western University, Canada, Social Sciences and Humanities Research Council of Canada
Responsible party
Lindsay P. Bodell, PhD (Associate Professor, Western University) — Principal investigator
First posted
Feb 11, 2026
Start date
Feb 1, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Aug 21, 2026

Study contacts

Genevieve M Bianchini, MSc
Contact
gbianch2@uwo.ca
519-661-2111 ext. 87316
Lindsay P Bodell, PhD
principal investigator · Western University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion